FGFR3 testing (SNVs and gene fusions) in Urothelial / Bladder cancer (FFPE).
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
02-FGFR-27
FGFR3 variants and fusions
NGS, PCR based, rtPCR
FFPE
English, French, German, Italian, Spanish
Pending
28/02/2027
Jun-27
June - August 2027
December 2027 - January 2028
Three mock clinical cases with matching human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE (designed to simulate real patient samples). One 10um or 15um FFPE section per case is provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Variant allele frequencies of any artificial FFPE reference materials have been validated using ddPCR.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test the samples according to their routine strategy, to return a clinical report and complete a data collection form. Laboratories are expected to provide information about their test scope and the technical and clinical limitations of their assays to enable accurate assessment.
Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Closes in 111 days
From £796.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
Questions about this scheme?
Contact our team
Express your interest in ''.